Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens

202052 citationsJournal Articlegreen Open Access

Authors

Michael Leonard · Vanderbilt University Medical Center

Zinhle Cindi · University of Cape Town

Yuki Bradford · University of Pennsylvania

Kassem Bourgi · Indiana University – Purdue University Indianapolis

John R. Koethe · Vanderbilt University Medical Center

Megan Turner · Vanderbilt University Medical Center

Jamison Norwood

Abstract

Among patients who switched from efavirenz- to INSTI-based therapy, CYP2B6 genotype was associated with weight gain, possibly reflecting withdrawal of the inhibitory effect of higher efavirenz concentrations on weight gain. The difference by concomitant nucleoside analogue is unexplained.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

Volume 73, Issue 7, pp. e2153-e2163

DOI: 10.1093/cid/ciaa1219

Field-Weighted Citation Impact: 0.79